Toshiharu Nagatsu

Prof. Dr. Toshiharu Nagatsu

orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
TNToshiharu Nagatsu
Toshiharu Nagatsu
MSM. Sawada
M. Sawada
Parkinsons disease (PD) is a movement disorder caused by degeneration of the nigrostriatal dopamine (DA) neurons in the substantia nigra pars compacta and the resultant deficiency in the neurotransmitter DA at the nerve terminals in the striatum. We and other investigators found increased levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6, and decreased levels of neurotrophins such as brain-derived neurotrophic factor (BDNF) in the nigrostriatal region of postmortem brains and/or in the ventricular or lumbar cerebrospinal fluid (CSF) from patients with sporadic PD, and in animal models, such as 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP)- and 6-hydroxydopamine (6-OHDA)-induced PD. These changes in cytokine and neurotrophin levels may be initiated by activated microglia, which may then promote apoptotic cell death and subsequent phagocytosis of DA neurons. Cytokines as pleiotropic factors, promote signals that either lead to cell death or exert neuroprotective effects. The discovery of toxic changes in trophic microglia by M. Sawada and co-workers is important to this point. Ultimately, microglial cells may regulate cellular changes that cause either harm or benefit by producing cytokines or neurotrophins depending upon the primary cause and the circumstances during the inflammatory process of PD.

1 January 2000
Verified
Book Chapter
Closed access
PDF file
TNToshiharu Nagatsu
Toshiharu Nagatsu
MMM. Mogi
M. Mogi
HIHiroshi Ichinose
Hiroshi Ichinose
ATA. Togari
A. Togari

1 October 1997 in Neuroscience Research
Verified
Journal Article
Closed access
TNToshiharu Nagatsu
Toshiharu Nagatsu

1 January 2009 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
TNToshiharu Nagatsu
Toshiharu Nagatsu
MSMakoto Sawada
Makoto Sawada

11 July 2018 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
TNToshiharu Nagatsu
Toshiharu Nagatsu
ANAkira Nakashima
Akira Nakashima
HIHiroshi Ichinose
Hiroshi Ichinose
KKKazuto Kobayashi
Kazuto Kobayashi

Verified
Journal Article
Open access
PDF file
TNToshiharu Nagatsu
Toshiharu Nagatsu
ANAkira Nakashima
Akira Nakashima
HWHirohisa Watanabe
Hirohisa Watanabe
Shosuke ItoShosuke Ito
Shosuke Ito
Kazumasa WakamatsuKazumasa Wakamatsu
Kazumasa Wakamatsu
Parkinson’s disease (PD) is an aging-related disease and the second most common neurodegenerative disease after Alzheimer’s disease. The main symptoms of PD are movement disorders accompanied with deficiency of neurotransmitter dopamine (DA) in the striatum due to cell death of the nigrostriatal DA neurons. Two main histopathological hallmarks exist in PD: cytosolic inclusion bodies termed Lewy bodies that mainly consist of α-synuclein protein, the oligomers of which produced by misfolding are regarded to be neurotoxic, causing DA cell death; and black pigments termed neuromelanin (NM) that are contained in DA neurons and markedly decrease in PD. The synthesis of human NM is regarded to be similar to that of melanin in melanocytes; melanin synthesis in skin is via DOPAquinone (DQ) by tyrosinase, whereas NM synthesis in DA neurons is via DAquinone (DAQ) by tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC). DA in cytoplasm is highly reactive and is assumed to be oxidized spontaneously or by an unidentified tyrosinase to DAQ and then, synthesized to NM. Intracellular NM accumulation above a specific threshold has been reported to be associated with DA neuron death and PD phenotypes. This review reports recent progress in the biosynthesis and pathophysiology of NM in PD.